Results 31 to 40 of about 33,732 (139)

Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate

Journal of Microbiology, Immunology and Infection, 2023
Background: Despite increasing concerns about the association between remdesivir and bradycardia in severe coronavirus disease 2019 (COVID-19) patients receiving remdesivir, information on its clinical course and precipitating factors is limited. Our aim
Yan-Zuo Chen, Ming-Shen Lin, Yi-Ping Lin, Yi-Zhan Liu, Chia-Jui Yang   +4 more
doaj   +1 more source

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study

Infectious Diseases and Therapy, 2023
Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, Kavita Juneja, Monica Ramchandani, Joshua T. Schiffer, Carlos Vaca, Robert L. Gottlieb, Yuan Tian, Emon Elboudwarej, Joshua A. Hill, Richard Gilson, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Jairo M. Montezuma-Rusca, Anu Osinusi, Roger Paredes   +17 more
doaj   +1 more source

The effect of remdesivir on selective biomarkers and its value in predicting the clinical outcome in patients with COVID-19

Asian Journal of Medical Sciences, 2021
Background: To the best of our knowledge, there have been no studies to evaluate the effect of remdesivir on inflammatory markers. Aims and Objectives: To study the effect of Remdesivir on Selective biomarkers namely C-Reactive Protein (CRP), Lactate ...
Sanjana Rai , Dyna Jones , Chinnappa Anjanappa Jayashankar , Venkata Bharat Kumar Pinnelli , Eashwer Manpreeth , Venkata Sai Raghava Prashanthi Seetha   +5 more
doaj   +1 more source

Remdesivir and its antiviral activity against COVID-19: A systematic review

Clinical Epidemiology and Global Health, 2021
Background: The aim of this study was to summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19. Methods: Available publications were systematically explored on some databases and gray literature was examined.
Andri Frediansyah, Firzan Nainu, Kuldeep Dhama, Mudatsir Mudatsir, Harapan Harapan   +4 more
doaj   +1 more source

Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study

Scientific Reports, 2022
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan.
Kazuhito Miyazaki, Yukihiro Yoshimura, Nobuyuki Miyata, Hiroaki Sasaki, Aya Shiba, Masaharu Aga, Yusuke Hamakawa, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Tsuneo Shimokawa, Hiroaki Okamoto, Natsuo Tachikawa   +12 more
doaj   +1 more source

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis

Case Reports in Infectious Diseases, 2020
Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials.
Vincent Peyko, Helena Ladd, Anthony Cutrona   +2 more
doaj   +1 more source

Safety and heart rate changes in Covid-19 patients treated with Remdesivir

International Journal of Infectious Diseases, 2021
Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir.
Natale Daniele Brunetti, MD, PhD, Mariacristina Poliseno, MD, Irene Francesca Bottalico, MD, Antonio Centola, MD, Laura Montemurro, MD, Salvatore Sica, MD, Teresa Santantonio, MD, Sergio Lo Caputo, MD   +7 more
doaj   +1 more source

Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study

Journal of Microbiology, Immunology and Infection
Background: Remdesivir has been used to treat severe coronavirus 2019 (COVID-19); however, its safety and effectiveness in patients remain unclear. This study aimed to investigate the safety and effectiveness of remdesivir in patients with COVID-19 with ...
Yan-Bo Huang, Chip-Jin Ng, Cheng-Hsun Chiu, Chung-Hsien Chaou, Shi-Ying Gao, Shou-Yen Chen   +5 more
doaj   +1 more source

Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility

Advanced Science, EarlyView.
We identify an antagonistic ubiquitin circuit that controls cellular permissiveness to multiple coronaviruses. The deubiquitinase USP7 stabilizes the epigenetic regulator KDM6A to upregulate viral receptors, while the E3 ligase RNF40 degrades KDM6A by catalyzing K6/K11‐ubiquitin chains of KDM6A for autophagic degradation.
Meng‐Zhuo Huang, Zhong‐Yuan Yang, Shi Wang, Yan Ge, Lan Lin, Mia Madel Alfajaro, Renata B. Filler, Wan‐Yao Song, Ming‐Zhu Kong, Jin Wei   +9 more
wiley   +1 more source

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Case Reports in Women's Health, 2020
Summary: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus ...
Jonathon Anderson, Jordan Schauer, Suzanne Bryant, Cornelia R. Graves   +3 more
doaj   +1 more source